Prescribing Luforbec by brand could still deliver cost improvements of up to £93.3 million per year across the UK11
Luforbec has already released list price savings of over £62 Million for the NHS and is now the most widely prescribed ICS/LABA pMDI in 28 ICB’s and Health Boards across the UK as of June 20258
Beclometasone/Formoterol pMDIs are listed as Category C medicines in the NHS Drug Tariff, therefore Luforbec must be prescribed by brand to release savings for the NHS6
If you would like to know more about Luforbec and the savings opportunities available, please get in touch by email to:
UKRespiratory@lupin.com or call on: 01565 751378
Through carbon offsetting Luforbec 100/6 and 200/6 pMDI are certified as Carbon Neutral products.12
To read more about how carbon neutrality for Luforbec is achieved, click here.
